Marin-Alejandre B, Abete I, Cantero I, et al. 2019

31652512

The Metabolic and Hepatic Impact of Two Personalized Dietary Strategies in Subjects with Obesity and Nonalcoholic Fatty Liver Disease: The Fatty Liver in Obesity (FLiO) Randomized Controlled Trial.

Marin-Alejandre B, Abete I, Cantero I, Monreal J, Elorz M,Herrero J, Benito-Boillos A, Quiroga J, Martinez-Echeverria A, Uriz-Otano J, Huarte-Muniesa M,T ur J, Martinez J, Zulet M

Nutrients

2019

11

10

Randomized Controlled Trial

Low risk

Overweight or obese (BMI >/= 27.5 kg/m2 to < 40 kg/m2); 40-80 years old; hepatic steatosis confirmed by abdominal ultrasonography.

Presence of known liver disease other than NAFLD; >/= 3 kg of body weight loss in the last 3 months; excessive alcohol consumption (>21 and >14 units of alcohol per week for men and women, respectively); endocrine disorders (hyperthyroidism or uncontrolled hypothyroidism); pharmacological treatment with immunosuppressants, cytotoxic agents, systemic corticosteroids (or other drugs that could potentially cause hepatic steatosis or altering liver tests); active autoimmune diseases or requiring pharmacological treatment; use of weight modifiers; severe psychiatric disorders; lack of autonomy or an inability to follow the diet; difficulties in following the scheduled visits.

To evaluate the effects of two personalized energy-restricted dietary strategies differing in several dietary factors (macronutrients, fiber, meal frequency, total antioxidant capacity, and Mediterranean diet adherence) on liver status, as assessed by imaging techniques and biochemical markers in overweight and obese subjects with NAFLD after a 6 months follow-up.

Spain

Government, Foundation

Health Department of the Government of Navarra, CIBERobn (Physiopathology of Obesity and Nutrition), Fundació La Marató de TV3, Principal author was supported by fellowships from Consejo Nacional de Ciencia y Tecnología (CONACYT) y el Estado de Michoacán